๐ Deployment of convalescent plasma for the prevention and treatment of COVID-19.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e. "convalescent") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. There are numerous examples, where convalescent plasma has been used successfully as post-exposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East Respiratory Syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads and improved survival. Globally, blood centers have robust infrastructure to undertake collections and construct inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource. .
keywords
๐ convalescent plasma (22)
๐ infectious disease (312)
๐ viral load (91)
๐ infectious diseases (94)
author
๐ค Bloch, Evan M
๐ค Shoham, Shmuel
๐ค Casadevall, Arturo
๐ค Sachais, Bruce S
๐ค Shaz, Beth
๐ค Winters, Jeffrey L
๐ค van Buskirk, Camille
๐ค Grossman, Brenda J
๐ค Joyner, Michael
๐ค Henderson, Jeffrey P
๐ค Pekosz, Andrew
๐ค Lau, Bryan
๐ค Wesolowski, Amy
๐ค Katz, Louis
๐ค Shan, Hua
๐ค Auwaerter, Paul G
๐ค Thomas, David
๐ค Sullivan, David J
๐ค Paneth, Nigel
๐ค Gehrie, Eric
๐ค Spitalnik, Steven
๐ค Hod, Eldad
๐ค Pollack, Lewis
๐ค Nicholson, Wayne T
๐ค Pirofski, Liise-Anne
๐ค Bailey, Jeffrey A
๐ค Tobian, Aaron Ar
year
โฐ 2020
journal
๐ J Clin Invest
issn
๐
volume
number
page
citedbycount
0
download
๐ [BibTeX]